Agile Therapeutics, Inc. (AGRX) EPS Estimated At $-0.23

February 24, 2018 - By Darrin Black

 Agile Therapeutics, Inc. (AGRX) EPS Estimated At $ 0.23
Investors sentiment increased to 1.35 in Q3 2017. Its up 0.74, from 0.61 in 2017Q2. It increased, as 9 investors sold Agile Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 23.16 million shares or 7.44% more from 21.56 million shares in 2017Q2 were reported.
Needham Inv Management Limited Company has invested 0.57% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX). 35,500 were reported by Janney Montgomery Scott Ltd. Pennsylvania-based Vanguard Grp Inc Inc has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). 1.25 million are owned by Cormorant Asset Ltd Liability. State Bank Of Mellon Corp reported 18,266 shares stake. Virtu Fincl Lc accumulated 0% or 83,806 shares. Glenmede Trust Na has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). The Massachusetts-based Acadian Asset Mngmt Limited Co has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Dimensional Fund Limited Partnership accumulated 0% or 95,820 shares. 1.82M were accumulated by Caxton. Millennium Mgmt Ltd Liability invested in 0% or 143,326 shares. Renaissance Llc accumulated 0% or 88,500 shares. 441,708 are held by Endurant Mngmt L P. Neuberger Berman Grp Limited Co stated it has 137,500 shares or 0% of all its holdings. California-based Franklin Resources Incorporated has invested 0.01% in Agile Therapeutics, Inc. (NASDAQ:AGRX).

Analysts expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to report $-0.23 EPS on March, 14.They anticipate $0.06 EPS change or 20.69 % from last quarter’s $-0.29 EPS. After having $-0.22 EPS previously, Agile Therapeutics, Inc.’s analysts see 4.55 % EPS growth. The stock decreased 0.54% or $0.02 during the last trading session, reaching $3.65. About 45,406 shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since February 24, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Among 6 analysts covering Agile Therapeutics (NASDAQ:AGRX), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Agile Therapeutics had 21 analyst reports since December 30, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Agile Therapeutics, Inc. (NASDAQ:AGRX) on Tuesday, October 10 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 2. The rating was maintained by Noble Financial with “Buy” on Monday, June 12. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, December 22. The rating was maintained by Cantor Fitzgerald on Monday, November 20 with “Buy”. On Tuesday, December 26 the stock rating was downgraded by William Blair to “Hold”. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) has “Buy” rating given on Friday, January 8 by Cantor Fitzgerald. The rating was maintained by Noble Financial with “Buy” on Tuesday, June 27. The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) has “Buy” rating given on Friday, July 28 by Noble Financial. William Blair downgraded the shares of AGRX in report on Friday, December 22 to “Hold” rating.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $124.78 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

More notable recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Reuters.com which released: “BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy …” on December 22, 2017, also Seekingalpha.com with their article: “Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look” published on December 27, 2017, Seekingalpha.com published: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” on September 05, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) were released by: Globenewswire.com and their article: “Agile Therapeutics to Present Additional Phase 3 Data at the North American …” published on September 28, 2017 as well as Globenewswire.com‘s news article titled: “Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its …” with publication date: October 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.